A Case of a Patient with Hepatocellular Carcinoma and Lung Metastasis Who Failed Sorafenib Treatment and Achieved Complete Remission after Lung Resection and Radiation Therapy.
- Author:
Jung Hwan YU
1
;
Jung Il LEE
Author Information
- Publication Type:Case Report
- Keywords: Sorafenib; Hepatocellular carcinoma; Neoplasm metastasis; Radiotherapy
- MeSH: alpha-Fetoproteins; Carcinoma, Hepatocellular*; Disease Progression; Drug Therapy; Humans; Lung Neoplasms; Lung*; Male; Neoplasm Metastasis*; Radiotherapy
- From:Journal of Liver Cancer 2017;17(1):77-81
- CountryRepublic of Korea
- Language:Korean
- Abstract: In hepatocellular carcinoma (HCC), sorafenib is the only approved systemic chemotherapy, and has been applied for those with advanced HCC especially with systemic metastasis. However, the treatment results are suboptimal leaving many cases with disease progression despite the use of optimum dose. There is no established guideline for those that fail to respond to sorafenib treatment. In this case, a 46-years-old male with metastatic lung cancer from HCC experienced progression despite sorafenib treatment. Then, the patient received surgical resection of the metastatic lung mass followed by radiation therapy and achieved complete remission for 10 months after the surgical treatment and radiation therapy. Alpha-fetoprotein level was normalized and complete remission has been maintained.
